Jazz Pharmaceuticals (JAZZ) Total Current Liabilities (2010 - 2026)

Jazz Pharmaceuticals' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $2.2 billion for Q1 2026.

• On a quarterly basis, Total Current Liabilities rose 83.75% year-over-year to $2.2 billion in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 83.75% increase from a year earlier, with the FY2025 full-year figure at $2.2 billion, up 115.92% from the prior year.
• Total Current Liabilities was little changed at $2.2 billion in Q1 2026 per JAZZ's latest filing, from $2.2 billion in the prior quarter.
• Across five years, Total Current Liabilities topped out at $2.3 billion in Q3 2025 and bottomed at $705.4 million in Q2 2022.
• The 5-year median for Total Current Liabilities is $1.2 billion (2025), against an average of $1.4 billion.
• Across the five-year window, Total Current Liabilities sank 34.54% in 2024 and surged 120.79% in 2025, its largest moves.
• Year by year, Total Current Liabilities stood at $933.2 million in 2022, then surged by 64.67% to $1.5 billion in 2023, then slumped by 32.42% to $1.0 billion in 2024, then jumped by 115.92% to $2.2 billion in 2025, then rose by 0.18% to $2.2 billion in 2026.
• Per Business Quant, the three latest JAZZ Total Current Liabilities figures stand at $2.2 billion (Q1 2026), $2.2 billion (Q4 2025), and $2.3 billion (Q3 2025).